M&A Deal Announcement | Tentt Deal Tracker

Tevogen Bio Holdings Inc. has entered into a letter of intent to evaluate a management services organization, a healthcare services other business in New Jersey, for $100 million. The proposed other acquisition would add MSO management services and may support contract research operations as Tevogen expands its healthcare infrastructure across its biotechnology arm and Tevogen.AI technology platform. Tevogen is also pursuing related CRO evaluation and other life sciences and healthcare-related acquisition initiatives to build a revenue-generating healthcare services arm in NJ. The non-exclusive, non-binding LOI remains subject to due diligence, definitive agreement, required approvals, and customary closing conditions, with the overall opportunity targeting approximately $100 million in combined annual revenue if consummated.